Cipher Wins Health Canada Review for Natroba Head Lice and Scabies Treatment

Cipher Pharmaceuticals ( (TSE:CPH) ) just unveiled an update.

Cipher Pharmaceuticals has had its new drug submission for Natroba (Spinosad), a treatment for head lice and scabies, accepted for review by Health Canada, marking a key regulatory step toward introducing the product to the Canadian market. Already marketed by Cipher in the U.S., Natroba is positioned as a more effective alternative to widely used but increasingly resistance-prone treatments such as permethrin, and the company plans to commercialize it directly through its existing Canadian sales and distribution network if approved, targeting a clear unmet need and potentially strengthening Cipher’s dermatology and parasitic-infection franchise in North America.

The most recent analyst rating on (TSE:CPH) stock is a Buy with a C$17.50 price target. To see the full list of analyst forecasts on Cipher Pharmaceuticals stock, see the TSE:CPH Stock Forecast page.

Spark’s Take on TSE:CPH Stock

According to Spark, TipRanks’ AI Analyst, TSE:CPH is a Outperform.

The score is driven primarily by strong financial performance (notably cash flow quality, profitability, and reduced leverage). Earnings-call takeaways reinforce the strength via Natroba-led growth and debt repayment, while technical indicators are modestly positive. Valuation appears reasonable, but the lack of dividend yield data and headwinds in licensing/Absorica temper the overall rating.

To see Spark’s full report on TSE:CPH stock, click here.

More about Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and development-stage products. The company focuses on acquiring therapies that address unmet medical needs, overseeing their clinical development and regulatory approvals, and marketing them in Canada, the United States and South America.

Average Trading Volume: 31,503

Technical Sentiment Signal: Buy

Current Market Cap: C$375.5M

For detailed information about CPH stock, go to TipRanks’ Stock Analysis page.